anpac_logo_full color_stacked.png
AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020
30 avr. 2021 16h45 HE | Anpac Bio, USA
SAN JOSE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in China and the...
anpac_logo_full color_stacked.png
AnPac Bio Reports Fiscal Year 2020 Annual Financial Results (89.1% Increase in Revenue and 20.7% Decrease in Net Loss)
30 avr. 2021 08h00 HE | Anpac Bio, USA
SAN JOSE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
anpac_logo_full color_stacked.png
AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020
16 avr. 2021 16h15 HE | Anpac Bio, USA
SAN JOSE, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
anpac_logo_full color_stacked.png
AnPac Bio Developed and Completed Evaluations of New Generation Cancer Detection Sensor with Improved Performance
09 mars 2021 07h30 HE | Anpac Bio, USA
SAN JOSE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United...
anpac_logo_full color_stacked.png
AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement
05 mars 2021 16h35 HE | Anpac Bio, USA
SAN JOSE, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United...
anpac_logo_full color_stacked.png
China’s NMPA Approved Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility)
08 févr. 2021 07h00 HE | Anpac Bio, USA
SAN JOSE, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United...
anpac_logo_full color_stacked.png
AnPac Bio Granted a New US patent on Novel Medical Device for Multi-Cancer Detection
01 févr. 2021 07h30 HE | Anpac Bio, USA
SAN JOSE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
anpac_logo_full color_stacked.png
AnPac Bio Makes Significant Progress in Detecting Pre-cancer Diseases and Recorded Over 20 Types of Pre-cancer Diseases
14 déc. 2020 07h30 HE | Anpac Bio, USA
SAN JOSE, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United...
VisionGate’s Cell-CT™ Platform Uses 3D Cell Morphometry and Artificial Intelligence to Detect an Immunotherapy Predictive Biomarker and Cancer-Associated Cells that have undergone Malignancy Associated Change (MAC) from Liquid Biopsy
24 sept. 2018 06h00 HE | VisionGate, Inc.
Seattle, WA, Sept. 24, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International...
OTraces’ TME Cancer Blood Test Presentation at Innovation Challenge Spurs Investor Interest from JP Morgan Healthcare Conference Participants
11 janv. 2018 13h39 HE | OTraces, Inc.
SAN FRANCISCO and BALTIMORE, Jan. 11, 2018 (GLOBE NEWSWIRE) -- OTraces Inc., a Sykesville, Maryland-based cancer diagnostics company with a unique patented and patent-pending blood test which...